Upper GI 2016

First page Previous page 170 Next page Last page

CROSS trial

368 patients

75% adenocarcinoma 25% squamous cell C.

RTCT mOS 34%

[HR 0.657; 95% CI 0.495-0.871; P=0.003]

Van Hagen et al. NEJM 2012

Made with